openPR Logo
Press release

Pompe Disease Market Growth Analysis up to 2024

04-16-2018 09:02 PM CET | Health & Medicine

Press release from: Transparency Market Research

Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies in the mutation of a gene responsible for production of the enzyme acid alpha-glycosidase. This enzyme breaks glycogen into simpler form i.e. glucose but a mutation in the GAA gene prevents this activity. The stoppage of glycogen breakdown causes massive cellular dysfunction, with the marked involvement of the cardiac, smooth, and skeletal muscle.

Pompes disease is categorized on the basis of disease severity, disease progression and age, such as infantile-onset, non-classic infantile-onset and late onset. Within few months of birth, the infantile onset of Pompes disease starts showing its symptoms such as enlarged liver(hepatomegaly),muscle weakness(myopathy), heart defect, and poor muscle tone (hypotony).The infants affected with this disease face challenges of weight gain as well as hampered growth and breathing problems. The affected infant may have large protruding tongue.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14102

If untreated, the infant may die of heart failure in the first year of life itself. Non-Classic infantile-onset is usually seen at the age of 1 year. The disease symptoms include poor motor skills and a delayed muscle progress .They may show signs of hearing impairment and abnormally large heart. The muscle weakness may seriously lead to breathing problems. The Late-onset marks its symptoms by later stages of childhood, adolescent age or in adulthood. This form of late onset is a bit milder than the previous ones and doesn’t involve heart. The muscle weakness is generally observed in the legs, trunk and breathing muscles. The progress of the disorder in the muscles controlling breathing will ultimately lead to the respiratory failure.

Pompes disease can occur in various age groups and population across the world. The occurrence of the disease is 1 in 40,000 births in the U.S. In many cases, the people suffering from Pompes Disease in late onset of the disease remain undiagnosed. The symptoms of Pompes Disease are observed due to the complete or partial deficiency of the GAA enzyme. Diagnosis of Pompe disease can be performed by GAA activity assay. The tests for the detection of Pompe disease are Sequencing of the GAA gene, GAA activity assay in blood, cultured amniocytes, chorionic villi and cultured skin fibroblasts, The marker, urinary hexose tetrasaccharide can be used to keep a track of patients suffering from Pompe disease and Cross Reactive Immunological Material (CRIM) analysis.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=14102

Pompe disease can be treated by symptomatic, supportive and disease-specific ways. As the disease involves impairment of cardiac, respiratory and muscular systems, the treatment necessitates requirement of specialists with expertise in all these disorders. Cardiologists, dieticians, pediatricians, orthopedists may need to co-ordinate and design a well collaborated treatment plan for the patient. The US Food and Drug Administration has approved an enzyme replacement therapy- Myozyme® for the infantile onset of Pompe disease suffering patients of less than 8 years old. Whereas Lumizyme® is used for patients older than 8 years of age. The genetically engineered human GAA enzyme is administered intravenously every two weeks.

Increasing developments in the gene therapy and enzyme replacement therapies are driving factors for the growth of Pompe Disease Market. However, affordability of the expensive therapy treatments may pose a potential threat to these markets in developing markets. Major market players in the field of Pompe Disease therapeutics are Genzyme, BioMarin Pharmaceutical, and Amicus Therapeutics.There are some key vendors like Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences, and Valerion Therapeutics.

View Report -

https://www.transparencymarketresearch.com/pompe-disease-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pompe Disease Market Growth Analysis up to 2024 here

News-ID: 1018639 • Views: 356

More Releases from Transparency Market Research

Venous Diseases Treatment Market to Expand at a CAGR of 6.8% from 2022 - 2031
Venous Diseases Treatment Market: Overview The venous diseases treatment market is estimated to attain a valuation of US$ 11.3 Bn by 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.8% from 2022 to 2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of
Medical Imaging Equipment Services Market Future Scope Analysis Report 2022-2031
Medical Imaging Equipment Services Market: Overview The medical imaging equipment services market is estimated to attain a valuation of US$ 29.2 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.1% from 2022 to 2031. The key objective of the TMR report is to offer a complete assessment of the global market including
Geriatric Care Services Market Revenue Share Detailed Analysis Report 2021-2028
Geriatric Care Services Market: Overview The geriatric care services market is estimated to attain a valuation of US$ 0.7 Bn by the end of 2028, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 5.3% from 2021 to 2028. The key objective of the TMR report is to offer a complete assessment of the global market including major
Medical Device Technologies Market - Current Trends and Future Opportunities Ana …
Medical Device Technologies Market: Overview The medical device technologies market is estimated to attain a valuation of US$ 662.7 Bn by the end of 2028, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.3% from 2021 to 2028. The key objective of the TMR report is to offer a complete assessment of the global market including major

All 5 Releases


More Releases for Pompe

Pompe Disease Therapeutic Market - Increasing prevalence of pompe disease in man …
Pompe Disease Therapeutic Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Pompe Disease Therapeutic Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor analysis. This comprehensive
Pompe Disease Drug Market Epidemiology 2030| Delveinsight
DelveInsight's Pompe Disease Market Insights, Epidemiology, and Market Forecast 2030 report delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Pompe Disease market report provides current treatment practices, emerging drugs, Pompe Disease market share of the individual therapies, current and forecasted Pompe Disease market Size
Pompe Disease Therapeutic Market - Attractive Growth Opportunities 2017 - 2025
Manufacturers are focusing on finding new solutions by expanding their pipeline to cater the demand for pompe disease therapeutics market. For instance, in September, 2017, Avrobio Inc. expanded their products pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes. Furthermore, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for
Pompe Disease Market Intelligence with Competitive Landscape 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market Size – Industry Share Report 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market : Size, Status and Forecast 2016 - 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies